AnaptysBio, Inc.
Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
About
CEO
Mr. Daniel R. Faga
Employees
117
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNGS
Address
10770 Wateridge Circle, San Diego, CA 92121-5801, United States
×
![Enlarged Chart]()
Oscillators
Invalid data format
Summary
Invalid data format
Moving Averages
Invalid data format
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 3, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Mar 10, 2025 | -1.55 | — | — | — |
| Nov 6, 2024 | -1.65 | -1.14 | 0.51 | -30.91% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 6 | — | 8 |
| Average estimate | — | -1.52 | — | -5.87 |
| Low estimate | — | -1.77 | — | -7.36 |
| High estimate | — | -1.08 | — | -4.50 |
| Last year EPS | — | -1.64 | — | -6.18 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-7.220%
Next qtr. (Mar 2025)
7.320%
Current year
-1.660%
Next year (Dec 2025)
4.970%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 17.16M | 10.29M | 63.18M | 75.00M | 8.00M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 132.28M | 88.80M | 98.50M | 80.03M | 99.34M |
| Selling general and admin | 41.95M | 36.64M | 21.49M | 18.85M | 16.09M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -157.07M | -115.15M | -56.81M | -23.88M | -107.43M |
| Non operating interest income | |||||
| Income | 18.87M | 7.55M | 431,000 | 3.96M | 10.98M |
| Expense | 18.08M | 21.11M | 1.45M | — | 1.04M |
| Other income expense | -7.34M | 12,000 | 37,000 | -11,000 | 1,000 |
| Pretax income | -163.62M | -128.70M | -57.80M | -19.93M | -97.49M |
| Tax provision | -4,000 | 24,000 | — | — | -152,000 |
| Net income | -163.62M | -128.72M | -57.80M | -19.93M | -97.34M |
| Basic EPS | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 |
| Diluted EPS | -6.08 | -4.57 | -2.11 | -0.73 | -3.60 |
| Basic average shares | 26.92M | 28.17M | 27.43M | 27.30M | 27.06M |
| Diluted average shares | 26.92M | 28.17M | 27.43M | 27.30M | 27.06M |
| EBITDA | -135.83M | -105.26M | -54.26M | -18.31M | -95.04M |
| Net income from continuing op. | -163.62M | -128.72M | -57.80M | -19.93M | -97.34M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 452.39M | 610.38M | 643.07M | 416.55M | 435.20M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 35.97M | 71.31M | 495.73M | 250.46M | 171.02M |
| Other short term investments | 354.94M | 369.93M | 52.37M | 143.20M | 203.21M |
| Accounts receivable | 6.85M | 1.42M | 876,000 | — | — |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 4.90M | 2.91M | 3.51M |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 9.08M | 4.55M | 4.90M | 2.91M | 3.51M |
| Non current assets | |||||
| Properties | 22.65M | 23.77M | 25.24M | 5.57M | 4.91M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 1.64M | 1.59M | 1.32M | 976,000 | 811,000 |
| Construction in progress | — | — | — | — | — |
| Leases | 203,000 | 203,000 | 203,000 | 527,000 | 575,000 |
| Accumulated depreciation | -6.22M | -5.58M | -4.92M | -4.95M | -4.68M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | 27.03M | 142.94M | 67.10M | 17.55M | 54.31M |
| Other non current assets | 256,000 | 256,000 | 256,000 | 318,000 | 1.54M |
| Total liabilities | 364.29M | 348.28M | 286.64M | 19.82M | 30.19M |
| Current liabilities | |||||
| Accounts payable | 4.70M | 2.78M | 1.74M | 4.22M | 16.24M |
| Accrued expenses | 23.77M | 16.25M | 8.68M | 11.57M | 8.90M |
| Short term debt | 1.78M | 1.64M | 1.51M | 342,000 | 2.25M |
| Deferred revenue | — | — | — | — | — |
| Tax payable | — | — | — | — | — |
| Pensions | 7.20M | 5.38M | 4.18M | 3.69M | 2.15M |
| Other current liabilities | — | — | — | — | 871,000 |
| Non current liabilities | |||||
| Long term debt | 16.04M | 17.81M | 19.45M | — | 654,000 |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 310.81M | 304.41M | 251.09M | — | 654,000 |
| Shareholders equity | |||||
| Common stock | 27,000 | 29,000 | 28,000 | 27,000 | 27,000 |
| Retained earnings | -614.10M | -450.48M | -321.75M | -263.96M | -244.03M |
| Other shareholders equity | -797,000 | -5.25M | -422,000 | -4,000 | 338,000 |
| Total shareholders equity | 88.10M | 262.10M | 356.43M | 396.73M | 405.01M |
| Additional paid in capital | 702.97M | 717.80M | 678.58M | 660.67M | 648.67M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | -163.62M | -128.72M | -57.80M | -19.93M | -97.34M | -61.66M | -30.07M | -4.26M | -5.41M | 3.53M | -5.55M |
| Depreciation | 2.38M | 2.34M | 2.09M | 1.62M | 1.41M | 315,000 | 183,000 | 233,000 | 274,000 | 308,000 | 580,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 33.21M | 27.36M | 15.35M | 11.50M | 12.41M | 9.96M | 4.38M | 1.16M | 604,000 | 160,000 | 151,000 |
| Other Non-Cash Items | 18.08M | 21.11M | 1.45M | — | 676,000 | 646,000 | 619,000 | 105,000 | 110,000 | 1.27M | 886,000 |
| Accounts Receivable | -5.43M | -543,000 | -876,000 | — | 174,000 | 1.43M | 3.74M | -4.12M | 229,000 | -1.46M | 268,000 |
| Accounts Payable | 10.94M | 9.70M | -4.74M | -7.69M | 13.20M | 7.08M | 2.22M | 1.25M | 1.95M | 482,000 | -255,000 |
| Other Assets & Liabilities | -1.64M | -1.51M | -72,000 | -1.18M | -999,000 | 139,000 | — | -3.08M | -9.08M | 10.76M | -1.39M |
| Operating Cash Flow | -106.09M | -70.27M | -44.60M | -15.69M | -70.46M | -42.09M | -18.93M | -8.71M | -11.32M | 15.06M | -5.31M |
| Investing Activities | |||||||||||
| Capital Expenditures | -807,000 | -358,000 | -1.35M | -569,000 | -805,000 | -1.06M | -290,000 | -50,000 | -238,000 | -140,000 | -37,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | -303.92M | -802.50M | -118.66M | -194.93M | -251.82M | -347.54M | -290.91M | — | — | — | — |
| Sale of Investments | 449.48M | 408.02M | 158.85M | 289.97M | 384.05M | 206.15M | 48.14M | — | — | — | — |
| Investing Cash Flow | 144.75M | -394.85M | 38.84M | 94.48M | 131.43M | -142.45M | -243.06M | -50,000 | -238,000 | -140,000 | -37,000 |
| Financing Activities | |||||||||||
| Long-Term Debt Issuance | — | — | — | — | — | — | — | 10.00M | — | 5.00M | — |
| Long-Term Debt Payments | — | — | — | -1.38M | -7.50M | -6.88M | — | — | — | — | — |
| Other Financing Charges | -11.77M | 32.19M | 249.75M | — | — | -182,000 | -1.60M | -1.40M | -1.45M | -85,000 | — |
| Financing Cash Flow | -59.30M | 44.02M | 252.30M | -2.25M | -11.99M | 213.54M | 290.94M | 8.60M | 39.24M | 4.92M | 1.96M |
| Other Cash Details | |||||||||||
| End Cash Position | 35.97M | 71.31M | 495.73M | 250.52M | 171.08M | 113.66M | 81.25M | 51.29M | 51.74M | 22.19M | 2.81M |
| Income Tax Paid | — | — | — | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | 4,000 | 424,000 | 1.04M | 1.09M | 354,000 | 326,000 | 8,000 | — |
| Free Cash Flow | -121.61M | -73.95M | -47.29M | -14.73M | -70.32M | -49.57M | -19.73M | -9.08M | -9.93M | 14.46M | -5.83M |
Error: Invalid format in Holders JSON file.
Article
Anaptys to Present at the Guggenheim SMID Cap Biotech Conference
SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, will present at the Guggenheim SMID Cap Biotech Conference on Wednesday, Feb. 5, 2025 at 1:00pm ET / 10:00am PT.
Feb 3, 2025
Article
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
WASHINGTON and SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab (IL-36R antagonist mAb), which has successfully completed two registration-enabling global Phase 3 trials, GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of imsidolimab in patients with Generalized Pustular Psoriasis (GPP).
Feb 3, 2025
Article
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Inspire Medical Systems (INSP) have performed compared to their sector so far this year.
Jan 27, 2025
